Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - AVADEL PHARMACEUTICALS PLC | avdlex-312.htm |
| EX-32.2 - EXHIBIT 32.2 - AVADEL PHARMACEUTICALS PLC | avdlex-322.htm |
| EX-32.1 - EXHIBIT 32.1 - AVADEL PHARMACEUTICALS PLC | avdlex-321.htm |
| EX-31.1 - EXHIBIT 31.1 - AVADEL PHARMACEUTICALS PLC | avdlex-311.htm |
| EX-23.2 - EXHIBIT 23.2 - AVADEL PHARMACEUTICALS PLC | avdlex-232.htm |
| EX-21.1 - EXHIBIT 21.1 - AVADEL PHARMACEUTICALS PLC | avdlex-211.htm |
| EX-10.46 - EXHIBIT 10.46 - AVADEL PHARMACEUTICALS PLC | avdlex-1046.htm |
| EX-10.45 - EXHIBIT 10.45 - AVADEL PHARMACEUTICALS PLC | avdlex-1045.htm |
| EX-10.44 - EXHIBIT 10.44 - AVADEL PHARMACEUTICALS PLC | avdlex-1044.htm |
| EX-10.43 - EXHIBIT 10.43 - AVADEL PHARMACEUTICALS PLC | avdlex-1043.htm |
| 10-K - 10-K - AVADEL PHARMACEUTICALS PLC | avdl201710k.htm |
CONSENT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-219016, 333-177591, 333-212585, 333-213154) and on Form S-3 (No. 333-183961) of Avadel Pharmaceuticals plc (formerly Flamel Technologies S.A.) of our report dated March 15, 2016, except for the effects of the revisions discussed in Note 1 (not presented herein) to the consolidated financial statements appearing under Item 8 of the Company’s 2016 annual report on Form 10-K, as to which the date is March 28, 2017, relating to the financial statements and financial statement schedule, which appears in this Form 10-K.
Lyon, France,
March 16, 2018
/s/ PricewaterhouseCoopers Audit
Represented by
/s/ Frédéric Charcosset
Frédéric Charcosset